Evidence map›Paper›PMID 36416304›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023

Renal Endothelial Cell-Targeted Extracellular Vesicles Protect the Kidney from Ischemic Injury.

Kaiyue Zhang, Rongrong Li, Xiaoniao Chen, Hongyu Yan, Huifang Li, Xiaotong Zhao, Haoyan Huang, Shang Chen, Yue Liu, Kai Wang and 5 more

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 83 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Kaiyue ZhangSchool of Medicine, Nankai University, Tianjin, 300071, China.
Rongrong LiSchool of Medicine, Nankai University, Tianjin, 300071, China.
Xiaoniao ChenBeijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Hongyu YanThe Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, 300071, China.
Huifang LiSchool of Medicine, Nankai University, Tianjin, 300071, China.
Xiaotong ZhaoHenan Key Laboratory of Medical Tissue Regeneration, Xinxiang Medical University, Xinxiang, Henan, 453003, China.
Haoyan HuangSchool of Medicine, Nankai University, Tianjin, 300071, China.
Shang ChenSchool of Medicine, Nankai University, Tianjin, 300071, China.
Yue LiuSchool of Medicine, Nankai University, Tianjin, 300071, China.
Kai WangThe Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, 300071, China.
Zhibo HanJiangxi Engineering Research Center for Stem Cell, Shangrao, Jiangxi, 334000, China.
Zhong-Chao HanJiangxi Engineering Research Center for Stem Cell, Shangrao, Jiangxi, 334000, China.
Deling KongThe Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, 300071, China.
Xiang-Mei ChenState Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, 100853, China.
Zongjin LiSchool of Medicine, Nankai University, Tianjin, 300071, China.ORCID 0000-0002-4603-3743
Nankai University · CNBeijing Tongren Hospital · CNShangrao Normal University · CNXinxiang Medical University · CN

Funding

National Key R&D Program of China 2017YFA0103200National Natural Science Foundation of China 81830060National Natural Science Foundation of China U2004126Tianjin Key Medical Discipline (Specialty) Construction Project TJYXZDXK-043ATianjin Natural Science Foundation 21JCZDJC00070
6 · The paper itself

Abstract

Endothelial cell injury plays a critical part in ischemic acute kidney injury (AKI) and participates in the progression of AKI. Targeting renal endothelial cell therapy may ameliorate vascular injury and further improve the prognosis of ischemic AKI. Here, P-selectin as a biomarker of ischemic AKI in endothelial cells is identified and P-selectin binding peptide (PBP)-engineered extracellular vesicles (PBP-EVs) with imaging and therapeutic functions are developed. The results show that PBP-EVs exhibit a selective targeting tendency to injured kidneys, while providing spatiotemporal information for the early diagnosis of AKI by quantifying the expression of P-selectin in the kidneys by molecular imaging. Meanwhile, PBP-EVs reveal superior nephroprotective functions in the promotion of renal repair and inhibition of fibrosis by alleviating inflammatory infiltration, improving reparative angiogenesis, and ameliorating maladaptive repair of the renal parenchyma. In conclusion, PBP-EVs, as an ischemic AKI theranostic system that is designed in this study, provide a spatiotemporal diagnosis in the early stages of AKI to help guide personalized therapy and exhibit superior nephroprotective effects, offering proof-of-concept data to design EV-based theranostic strategies to promote renal recovery and further improve long-term outcomes following AKI.

Indexed as

Acute Kidney InjuryExtracellular VesiclesEndothelial CellsHumansIschemiaKidneyP-SelectinP-Selectinacute kidney injuryendothelial cellextracellular vesicleP-selectin binding peptidetheranostics

Identifiers

PMID36416304
PMCPMC9875634
OpenAlexW4309765082

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.